Document Detail

Adverse reactions attributed to sumatriptan. A postmarketing study in general practice.
MedLine Citation:
PMID:  7875179     Owner:  NLM     Status:  MEDLINE    
There are several reports on cardiac adverse reactions attributed to the antimigraine drug sumatriptan in the recent literature. In order to assess the frequency and the character of adverse reactions to sumatriptan, a postmarketing cohort study was performed one year after registration of the drug in The Netherlands. With assistance of 86% of the drug dispensing general practitioners in The Netherlands, 1727 patients who had received sumatriptan were traced in July, 1992. Via their general practitioners, a questionnaire about use of sumatriptan, adverse reactions and other medication was sent to the patients in December 1992. During the study period, seven patients were lost to follow-up. Of the 1720 remaining patients, 1202 (70%) responded to the questionnaire, of whom 1187 had actually used sumatriptan. The most frequently reported suspected adverse reactions were paraesthesiae (139 patients, 95% CI 9.9%-13.5%) and dizziness (96 patients, 95% CI 6.5%-9.7%). Chest pain after use of sumatriptan was reported by 94 patients (7.9%, 95% CI 6.4%-9.4%), and according to the close temporal relationship with the intake of sumatriptan and a positive rechallenge, a causal relationship was probable in most of those patients. The frequency of chest pain attributed to sumatriptan was higher in females (9.0% vs 4.6%; relative risk 1.9, 95% CI 1.1-3.4). Age and hypertension were not associated with chest pain attributed to sumatriptan. Dyspnoea attributed to sumatriptan was reported by 26 patients (2.2%), and was associated with obstructive lung disease (relative risk 5.4 95% CI 1.7-16.9).(ABSTRACT TRUNCATED AT 250 WORDS)
J P Ottervanger; T B van Witsen; H A Valkenburg; D E Grobbee; B H Stricker
Related Documents :
23993249 - Reasons driving treatment modification in parkinson's disease: results from the cross-s...
8530279 - Headache associated with transient ischemic attacks.
2335479 - A prospective study of chronic or recurrent headache in systemic lupus erythematosus.
17137539 - Migraine: a better way to recognize and treat it.
16606929 - Prolonged but reversible migraine-like episodes long after cranial irradiation.
1518439 - Proceedings of the discussion, "tolerability and safety of sandostatin".
16998359 - Treatment evolution in high-risk congenital diaphragmatic hernia: ten years' experience...
25313569 - Carboplatin hypersensitivity: evaluation and successful desensitization protocol.
15538159 - Computed tomography features of portal hypertensive gastropathy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  47     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  1994  
Date Detail:
Created Date:  1995-04-06     Completed Date:  1995-04-06     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  305-9     Citation Subset:  IM    
Netherlands Centre for Monitoring of Adverse Reactions to Drugs, Rijswijk.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chest Pain / chemically induced
Follow-Up Studies
Myocardial Infarction / chemically induced
Product Surveillance, Postmarketing*
Sumatriptan / adverse effects*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report f...
Next Document:  Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in J...